Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)
Identifieur interne : 002360 ( Main/Exploration ); précédent : 002359; suivant : 002361Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)
Auteurs : Peter A. Lewitt [États-Unis] ; M. Guttman [Canada] ; James W. Tetrud [États-Unis] ; Paul J. Tuite [États-Unis] ; Akihisa Mori [Japon] ; Philip Chaikin [États-Unis] ; Neil M. Sussman [États-Unis]Source :
- Annals of Neurology [ 0364-5134 ] ; 2008-03.
Abstract
Based on new understanding of nondopaminergic pathways involved in Parkinson's disease (PD) pathophysiology, a selective adenosine A2A receptor antagonist, istradefylline, shows promise for the treatment of PD.
Url:
DOI: 10.1002/ana.21315
Affiliations:
- Canada, Japon, États-Unis
- Californie, Michigan, Minnesota, New Jersey, Ontario
- Tokyo, Toronto
- Université de Toronto
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000E63
- to stream Istex, to step Curation: 000E63
- to stream Istex, to step Checkpoint: 000965
- to stream Main, to step Merge: 002555
- to stream Main, to step Curation: 002360
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)</title><author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name></author><author><name sortKey="Guttman, M" sort="Guttman, M" uniqKey="Guttman M" first="M." last="Guttman">M. Guttman</name></author><author><name sortKey="Tetrud, James W" sort="Tetrud, James W" uniqKey="Tetrud J" first="James W." last="Tetrud">James W. Tetrud</name></author><author><name sortKey="Tuite, Paul J" sort="Tuite, Paul J" uniqKey="Tuite P" first="Paul J." last="Tuite">Paul J. Tuite</name></author><author><name sortKey="Mori, Akihisa" sort="Mori, Akihisa" uniqKey="Mori A" first="Akihisa" last="Mori">Akihisa Mori</name></author><author><name sortKey="Chaikin, Philip" sort="Chaikin, Philip" uniqKey="Chaikin P" first="Philip" last="Chaikin">Philip Chaikin</name></author><author><name sortKey="Sussman, Neil M" sort="Sussman, Neil M" uniqKey="Sussman N" first="Neil M." last="Sussman">Neil M. Sussman</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4C849F98158530925A8AC68C2925986ABA4BA92E</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/ana.21315</idno><idno type="url">https://api-v5.istex.fr/document/4C849F98158530925A8AC68C2925986ABA4BA92E/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000E63</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000E63</idno><idno type="wicri:Area/Istex/Curation">000E63</idno><idno type="wicri:Area/Istex/Checkpoint">000965</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000965</idno><idno type="wicri:doubleKey">0364-5134:2008:Lewitt P:adenosine:a:a</idno><idno type="wicri:Area/Main/Merge">002555</idno><idno type="wicri:Area/Main/Curation">002360</idno><idno type="wicri:Area/Main/Exploration">002360</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)</title><author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name><affiliation></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Department of Neurology, Wayne State University School of Medicine, Detroit</wicri:cityArea></affiliation><affiliation></affiliation></author><author><name sortKey="Guttman, M" sort="Guttman, M" uniqKey="Guttman M" first="M." last="Guttman">M. Guttman</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Tetrud, James W" sort="Tetrud, James W" uniqKey="Tetrud J" first="James W." last="Tetrud">James W. Tetrud</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>The Parkinson Institute, Sunnyvale</wicri:cityArea></affiliation></author><author><name sortKey="Tuite, Paul J" sort="Tuite, Paul J" uniqKey="Tuite P" first="Paul J." last="Tuite">Paul J. Tuite</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Minnesota</region></placeName><wicri:cityArea>Department of Neurology, University of Minnesota, Minneapolis</wicri:cityArea></affiliation></author><author><name sortKey="Mori, Akihisa" sort="Mori, Akihisa" uniqKey="Mori A" first="Akihisa" last="Mori">Akihisa Mori</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Kyowa Hakko Kogyo Co., Ltd., Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Chaikin, Philip" sort="Chaikin, Philip" uniqKey="Chaikin P" first="Philip" last="Chaikin">Philip Chaikin</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Kyowa Pharmaceutical, Inc., Princeton</wicri:cityArea></affiliation></author><author><name sortKey="Sussman, Neil M" sort="Sussman, Neil M" uniqKey="Sussman N" first="Neil M." last="Sussman">Neil M. Sussman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Kyowa Pharmaceutical, Inc., Princeton</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-03">2008-03</date><biblScope unit="volume">63</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="295">295</biblScope><biblScope unit="page" to="302">302</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">4C849F98158530925A8AC68C2925986ABA4BA92E</idno><idno type="DOI">10.1002/ana.21315</idno><idno type="ArticleID">ANA21315</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Based on new understanding of nondopaminergic pathways involved in Parkinson's disease (PD) pathophysiology, a selective adenosine A2A receptor antagonist, istradefylline, shows promise for the treatment of PD.</div></front></TEI><affiliations><list><country><li>Canada</li><li>Japon</li><li>États-Unis</li></country><region><li>Californie</li><li>Michigan</li><li>Minnesota</li><li>New Jersey</li><li>Ontario</li></region><settlement><li>Tokyo</li><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="États-Unis"><region name="Michigan"><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name></region><name sortKey="Chaikin, Philip" sort="Chaikin, Philip" uniqKey="Chaikin P" first="Philip" last="Chaikin">Philip Chaikin</name><name sortKey="Sussman, Neil M" sort="Sussman, Neil M" uniqKey="Sussman N" first="Neil M." last="Sussman">Neil M. Sussman</name><name sortKey="Tetrud, James W" sort="Tetrud, James W" uniqKey="Tetrud J" first="James W." last="Tetrud">James W. Tetrud</name><name sortKey="Tuite, Paul J" sort="Tuite, Paul J" uniqKey="Tuite P" first="Paul J." last="Tuite">Paul J. Tuite</name></country><country name="Canada"><region name="Ontario"><name sortKey="Guttman, M" sort="Guttman, M" uniqKey="Guttman M" first="M." last="Guttman">M. Guttman</name></region></country><country name="Japon"><noRegion><name sortKey="Mori, Akihisa" sort="Mori, Akihisa" uniqKey="Mori A" first="Akihisa" last="Mori">Akihisa Mori</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002360 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002360 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4C849F98158530925A8AC68C2925986ABA4BA92E
|texte= Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)
}}
| This area was generated with Dilib version V0.6.29. |  |